Foresite Capital Management II, LLC - Q2 2022 holdings

$79.3 Million is the total value of Foresite Capital Management II, LLC's 1 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .

 Value Shares↓ Weighting
TXG  10x Genomics, Inc.$79,347,000
-40.5%
1,753,5280.0%100.00%0.0%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-08-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Epizyme, Inc.29Q4 202111.9%
Acceleron Pharma Inc.24Q3 20214.8%
Aerie Pharmaceuticals, Inc.22Q1 202040.3%
10x Genomics, Inc.17Q3 2023100.0%
Aimmune Therapeutics, Inc.17Q3 201941.0%
Alder BioPharmaceuticals, Inc.16Q3 201912.6%
Zafgen, Inc.12Q3 201733.5%
BioDelivery Sciences International, Inc.12Q1 20193.2%
Insmed Incorporated11Q1 202013.8%
Adaptimmune Therapeutics PLC9Q4 201811.3%

View Foresite Capital Management II, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2023-11-13
13F-HR2023-08-11
13F-HR2023-05-12
13F-HR2023-02-13
13F-HR2022-11-14
13F-HR2022-08-12
13F-HR2022-05-13
13F-HR2022-02-11
13F-HR2021-11-12
13F-HR2021-08-16

View Foresite Capital Management II, LLC's complete filings history.

Compare quarters

Export Foresite Capital Management II, LLC's holdings